The rename from PCOS to Polyendocrine Metabolic Ovarian Syndrome (PMOS) reflects a shift toward understanding the condition as metabolic-first. That reframing changes how a peptide research protocol should be organized — not by symptom, but by which of the underlying dysfunctions you’re addressing.
Root Dysfunction 1: Insulin Resistance
This is where the GLP-1 class has the strongest peptide evidence for PMOS specifically — research on semaglutide and tirzepatide has shown improvements in insulin sensitivity and downstream hormonal markers that extend beyond simple weight loss.
Root Dysfunction 2: Androgen Excess
Addressing insulin resistance often has a secondary effect on androgen levels, since elevated insulin drives ovarian androgen production. This is why the GLP-1 pathway is considered relevant to PMOS beyond weight management alone — it’s addressing an upstream driver.
Root Dysfunction 3: LH/FSH Dysregulation
Kisspeptin’s research on triggering ovulation without the hyperstimulation risk associated with some fertility interventions is the most direct peptide angle on this specific dysfunction, particularly relevant for those in the fertility-focused phase of PMOS management.
Root Dysfunction 4: Chronic Inflammation
KPV’s anti-inflammatory research profile is the most targeted peptide angle here, alongside BPC-157’s broader tissue and gut-focused repair research, which has some overlap with the chronic low-grade inflammation pattern seen in PMOS.
Building Your Own Protocol
Most people researching PMOS aren’t addressing all four dysfunctions equally — bloodwork (fasting insulin, androgen panel, LH/FSH ratio, inflammatory markers) can help identify which dysfunction is most pronounced for you, which is a more useful starting point than a generic combined stack.